(Q34555917)

3 August 2017

1 reference

title

Contribution to variability in response to opioids (English)

1 reference

3 August 2017

0 references

1

Geoffrey W Hanks

1 reference

3 August 2017

Colette Reid

2

1 reference

3 August 2017

publication date

10 December 2004

1 reference

Supportive Care in Cancer

3 August 2017

published in

1 reference

3 August 2017

volume

13

1 reference

3 August 2017

issue

3

1 reference

3 August 2017

page(s)

145-152

1 reference

The bioavailability and pharmacokinetics of morphine after intravenous, oral and buccal administration in healthy volunteers

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00520-004-0730-2

Comparisons of the Analgesic Effects of Oral and Intramuscular Oxymorphone and of Intramuscular Oxymorphone and Morphine in Patients with Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00520-004-0730-2

The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00520-004-0730-2

Intravenous fentanyl kinetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00520-004-0730-2

Opioids, confusion and opioid rotation

21 January 2018

1 reference

12 December 2020

Neurophysiology of opioid poorly responsive pain

1 reference

12 December 2020

The polymorphism A118G of the human mu-opioid receptor gene decreases the pupil constrictory effect of morphine-6-glucuronide but not that of morphine

1 reference

12 December 2020

Delirium in terminally ill cancer patients

1 reference

12 December 2020

Genetic basis of drug metabolism.

1 reference

12 December 2020

The WHO analgesic ladder for cancer pain management. Stepping up the quality of its evaluation

1 reference

12 December 2020

Clinical pharmacokinetics of morphine

1 reference

12 December 2020

Pharmacology of morphine and morphine-3-glucuronide at opioid, excitatory amino acid, GABA and glycine binding sites

1 reference

12 December 2020

Plasma morphine and morphine-6-glucuronide during chronic morphine therapy for cancer pain: plasma profiles, steady-state concentrations and the consequences of renal failure

1 reference

12 December 2020

Pain, the physiological antagonist of opioid analgesics

1 reference

12 December 2020

Analgesic Effect of Morphine Glucuronides

1 reference

12 December 2020

Ketamine as an adjuvant to opioids for cancer pain

1 reference

12 December 2020

Switching from morphine to oral methadone in treating cancer pain: what is the equianalgesic dose ratio?

1 reference

12 December 2020

Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone.

1 reference

12 December 2020

Differential effects of NMDA and group I mGluR antagonists on both nociception and spinal cord protein kinase C translocation in the formalin test and a model of neuropathic pain in rats

1 reference

12 December 2020

Nociceptive stimulation prevents development of tolerance to narcotic analgesia

1 reference

12 December 2020

The pharmacokinetics of oxycodone in uremic patients undergoing renal transplantation.

1 reference

12 December 2020

Unexpected complication of successful nerve block. Morphine induced respiratory depression precipitated by removal of severe pain.

1 reference

12 December 2020

Inhibition by fluoxetine of cytochrome P450 2D6 activity.

1 reference

12 December 2020

Morphine intoxication in renal failure: the role of morphine-6-glucuronide

1 reference

12 December 2020

Chronic nausea and morphine-6-glucuronide

1 reference

12 December 2020

The World Health Organization three-step analgesic ladder comes of age

1 reference

12 December 2020

Disposition of methadone in man after a single oral dose

1 reference

12 December 2020

Synthesis and identification of metabolites resulting from the biotransformation of DL-methadone in man and in the rat

1 reference

12 December 2020

Explanation for potency of repeated oral doses of morphine?

1 reference

12 December 2020

Experimental pain stimulates respiration and attenuates morphine-induced respiratory depression: a controlled study in human volunteers

1 reference

12 December 2020

The neurobiology of opiate tolerance, dependence and sensitization: mechanisms of NMDA receptor-dependent synaptic plasticity

1 reference

12 December 2020

Randomized placebo-controlled trial of the activity of the morphine glucuronides

1 reference

12 December 2020

Opioid rotation for toxicity reduction in terminal cancer patients

1 reference

12 December 2020

Strategies to manage the adverse effects of oral morphine: an evidence-based report.

1 reference

12 December 2020

Retrospective study of the use of hydromorphone in palliative care patients with normal and abnormal urea and creatinine.

1 reference

12 December 2020

Hydromorphone metabolites: isolation and identification from pooled urine samples of a cancer patient

1 reference

12 December 2020

Opioid rotation for cancer pain: rationale and clinical aspects

1 reference

12 December 2020

Clinical pharmacokinetics of fentanyl and its newer derivatives.

1 reference

12 December 2020

The pharmacology of mu analgesics: from patients to genes

1 reference

12 December 2020

A polymorphism (A118G) in the mu-opioid receptor gene affects the response to morphine-6-glucuronide in humans

1 reference

12 December 2020

the apparent affinity of morphine-3-glucuronide at μ1-opioid receptors results from morphine contamination: demonstration using HPLC and radioligand binding

1 reference

12 December 2020

A review of oxycodone's clinical pharmacokinetics and pharmacodynamics

1 reference

12 December 2020

Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer

1 reference

12 December 2020

Morphine in cancer pain: modes of administration. Expert Working Group of the European Association for Palliative Care

1 reference

12 December 2020

Hydromorphone-3-glucuronide: a more potent neuro-excitant than its structural analogue, morphine-3-glucuronide.

1 reference

12 December 2020

Blood-brain barrier permeability to morphine-6-glucuronide is markedly reduced compared with morphine

1 reference

12 December 2020

10.1007/S00520-004-0730-2

Identifiers

DOI

1 reference

3 August 2017

1 reference